Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

By sjmartinez • April 25, 2023

Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, Krige D, Carter J, Cox C, Patel M, Parfitt L, Powell M, Rosen L. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). J Immunother Cancer. 2023 Apr;11(4):e006561. doi: 10.1136/jitc-2022-006561. PMID: 37094988.

Tags: clinical trials as topic, Hematology/Oncology, immunotherapy, Investigational, oncolytic viruses, Publications, Therapies

Related Posts

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng[...]

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein[...]

Answering real-world clinical questions using large language model, retrieval-augmented generation, and agentic systems

Low YS, Jackson ML, Hyde RJ, Brown RE, Sanghavi NM, Baldwin JD, Pike CW, Muralidharan J, Hui G, Alexander N, Hassan H, Nene RV, Pike[...]